Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Qiagen Digital Insights launches NGS analysis for somatic cancer

March 2024—Qiagen Digital Insights announced its enhanced CLC Genomics Workbench Premium with LightSpeed technology now supports next-generation sequencing for somatic cancer secondary analysis. The software accelerator converts raw sequencing data in FASTQ files to interpretable lists of genetic variants in variant call format files. Qiagen says LightSpeed can analyze a 275-gene comprehensive cancer panel at 3377× coverage in six minutes for less than $0.72 per test within standard cloud environments, or laboratories can run the Qiagen CLC LightSpeed technology on existing local hardware with similar performance.

BD Biosciences releases RealBlue reagents

March 2024—BD Biosciences has released its BD Horizon RealBlue 744 and 705 laser-specific reagents, designed to reduce spillover and well suited for low- to medium-expression surface and intracellular markers. RB 744 can be used on five-laser BD FacSymphony analyzers and spectral flow cytometers. RealBlue 705 is an alternative to BD PerCP-Cy5.5 and BD Brilliant Blue 700 reagents and is compatible with conventional and spectral flow cytometry.

StatLab launches PiSmart slide printer

February 2024—StatLab announced the availability of its PiSmart thermal transfer slide printer for the automated printing of histology slides with patient information in three to five seconds. The slide printer connects with all on-market LIS systems or can be used as a standalone printer. The printer incorporates two hoppers for preloading different slide types. The single-slide manual load option allows users to bypass the hoppers when needed. PathSmart tracking software is included.

New chapter in digital pathology

February 2024—Advancements in whole slide imaging, integration of AI, and global collaboration networks are three areas the new president of the Digital Pathology Association highlighted in his first communication with DPA members this year.

Verichem bilirubin, urine chemistry reference materials

February 2024—Verichem Laboratories now offers its Tru-Zero Bilirubin Standard as part of the company’s line of liquid-stable and protein-based total and direct bilirubin clinical reference materials. The standard is intended to be treated as a patient specimen and features universal instrument compatibility. The concentration level for the total and direct bilirubin assays is 0.0 mg/dL. The product has an open-vial stability claim of five days and a shelf life of 14 months when stored at 2° to 8°C.

Machaon offers updated aHUS genetic panel

February 2024—Machaon Diagnostics has updated its genetic panel for detecting atypical hemolytic uremic syndrome. The aHUS genetic panel 3.0 now includes two more genes, for a total of 22, associated with thrombotic microangiopathies, including aHUS, thrombotic thrombocytopenic purpura, C3 glomerulopathy, congenital B12 deficiency, and others. Turnaround time is one week.

FormaPath, UB CAT announce clinical R&D collaboration

February 2024—FormaPath and the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UB CAT) announced their collaboration to further test and develop FormaPath’s AdiPress, an automated lymph node dissection device.

CLSI introduces country-based pricing model

February 2024—The Clinical and Laboratory Standards Institute has implemented new country-based pricing for countries that meet economic criteria set forth by the World Bank. Under this model, low- and lower-middle income countries receive a 90 percent discount off list prices and upper-middle income countries receive a 50 percent discount. The CLSI says that the pricing structure enables laboratories and clinicians around the world, regardless of resources, to more feasibly access its library of standards documents, training and support materials, and membership.

Horiba launches next-gen HELO hematology solution

February 2024—Horiba Medical has launched the CE-IVDR–approved HELO 2.0 high-throughput automated hematology platform. The platform is composed of the Yumi­zen H1500 and H2500 high-throughput hematology analyzers, Yumizen T6000 automated conveyor, Yumizen P8000 middleware and expert validation station, and Yumizen SPS automatic slide maker. In addition, CellaVision digital cell morphology systems can be integrated with the P8000 middleware.

Thermo Fisher, Aesku sign distribution agreement

February 2024—Thermo Fisher Scientific announced an exclusive distribution agreement with Aesku Group to market, sell, and support Aesku’s portfolio of FDA-cleared immunofluorescence products, automated instruments, and software in the United States. The agreement expands Thermo Fisher’s immunology product portfolio of Elia autoimmune diagnostics, ImmunoCap allergy diagnostics, and Phadia systems to include complementary reagents and systems from Aesku.

MARKETPLACE

TRENDING